PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.
NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.
Div Payout %, NP Margin, ROE, DY, QoQ Δ & YoY Δ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.
sapurakencanaif business is so easy to earn money,i will invest in actual manufacturing rather than invest in share market.
08/08/2020 2:54 PM
MariYahiMariYahoIf I’m u al, I will hoot 25 k and ready for limit up , then ciao
08/08/2020 8:13 PM
sapurakencanau can try,i dont mind because money is yours!
09/08/2020 10:21 AM
Joseph2020Has Texchem registered with the Medical Device Authority (MDA) of Malaysia for the establishment license to commence the sale of its PPE products? This is very important for supplier. If everyone can venture into this business, end of the day, the distributors eventually will select who is qualified to be the supplier. Consumer will choose reliable product and it involves in "life and death"
CAF-POWDon't chase too high......according to thestar, face masks are facing glut in China, due to low barrier of entry...
A report by AFP stated that in China, the tens of thousands of mask-making companies that mushroomed following the coronavirus pandemic are now struggling to survive.
This has come about after some 73,000 companies registered as mask makers in the first half of the year – including over 36,000 new companies in April alone – as prices and demand soared, the report indicated.
BuLLRamYesterday IB went limit up ,,premature ejaculation...quickly pulled out....n collect cheap...today the real real Fffed limit up...wakakaka....kokokokokokkkk
10/08/2020 11:26 AM
Fundamentalist91seeing price this high up, even the Japanese boss is starting to sell his stock, and these people are still buying. Really gamble without knowledge
edward96Recommend pecca for those who is late here. Have been having good lead on PPE, buying more machines to increase production, applying FDA, main business partners (perodua) all time high sales, havent include other clients, have been making profit all these time.
10/08/2020 2:32 PM
DaddyShakeAll these goreng counters might get freeze tonight!
longtermvaluegainDNONCE TECHNOLOGY Key Highlights • Significant improvement in Profit Before Tax (“PBT”) from loss of RM3.34 million in 1H Year-to-date (“YTD”) 30 June 2019 to RM2.40 million, an increase of RM5.74 million or 172% for Financial Year Ended 30 April 2020 (“FYE 30 April 2020”). • Noteworthy surge in revenue, average monthly sales for July 2019 till April 2020 was RM14.6 million compared with January 2019 till June 2019 of RM13.3 million representing a 9.8% increase, even though March and April sales were impacted by the Covid-19 induced MCO • Three consecutive profitable quarters with FYE PBT of RM2.40 million signifying 9 straight months of profit until April since the new management took over the running of the Company. D’nonce Technology Bhd (“D’nonce” or “the Group”) (“7114”), today announced its interim financial results for the sixth quarter (“Q6”) and 16-month consolidated financial results for its Financial Year Ended 30 April 2020 (“FYE 30 April 2020”). DNONCE is a diversified engineering solutions provider, serving customers in the semiconductor, automotive, medical/healthcare, data storage hardware and consumer electronics industries with overseas subsidiaries in Thailand. In mid-July 2019, D’nonce had installed a new Board of Directors and management, led by Mr. Tho Yow Yin as CEO. Under the new leadership. DNONCE embarked on costcutting measures and redirected their focus to expand the Group’s growth in value-added businesses. These efforts have borne positive results as reflected in its financial performance since July 2019 to 30 April 2020. D’nonce recorded a revenue of RM225 million for the FYE 30 April 2020, of which from 1 July 2019 to 30 April 2020, the Group recorded an average monthly revenue of RM14.6 million as compared to an average monthly revenue of RM13.3 million from 1 January 2019 to 30 June 2019, representing a 9.8% improvement in sales, despite the MCO which impacted operations in March and April 2020. The significant increment of the revenue was partly contributed by the surge in demand from customers in the healthcare industry mainly due to the Covid-19 outbreak as D’nonce provides essential support to the glove industry in Southern Thailand and also supplies injection molded ventilator parts from their factory in Prai, Pulau Pinang. Simultaneously, DNONCE continued to showcase a healthy and growing PBT having recorded a PBT of RM2.40 million for the Financial Period Ended 30 April 2020 reflecting a turnaround of RM5.74 million or 172% growth over the 1H Loss Before Tax of RM3.34 million. With the exception of Q6 FY2020 (which consisted of only 1 month), the Group achieved three consecutive quarters in the black (cumulative PBT of RM5.74 million from 1 July 2019 to 30 April 2020) - after losses earlier in the financial year throughout the first two quarters (cumulative Loss Before Tax of RM3.34 million from 1 January 2019 to 30 June 2019).
This is the result of the DNONCE Management’s continuous prudence in managing its expenses while expanding revenue, resulting in the highest level of operational efficiency and also the continuous growth of its business. As of 30th April 2020 the Group has generated a positive cash flow of RM8.16 million from operating activities and have cash and bank balances of RM32.5 million. For the full FYE 30 April 2020, D’nonce recorded a Profit After Tax of RM0.73 million (after the non-cash adjustment from the revaluation of properties deficit of RM0.45 million) in spite of the net losses recorded for Financial Period Ended 30 June 2019. Notwithstanding the challenging environment, DNONCE is cautiously optimistic of its business with the expectation of continued strong demand for its supplies to the medical and health sectors as well as the positive demand from the electronic technology sector moving forward. DNONCE has active initiatives underway to enhance its overall organisational effectiveness. These initiatives should increase productivity and cost efficiency while also helping to realise scale economies as Dnonce continues to grow its commercial opportunities.
两大利好围绕DNONCE！！ 1）Provides Essential Support (Glove Industry) Southern Thailand
2） Injection Molded Ventilator Parts (Prai, Pulau Pinang)
预料，DNONCE 可突破RM1.00大关。
19/08/2020 8:01 AM
GeneTakavicwhy japanese owner keeps disposing shares?
ironman118Q3 2020 just announced today. Company has turned around in Q3 2020 with EPS of 6.04 sen. The share price is closed at 64 sen today. If net profit can be achieved consistently for the next 4 quarters, EPS will be 24 sen. The share price will be undervalued at PE 10.
ironman118Tasco also announced very good performance yesterday. Its Q2 2020 EPS is 5.35 sen. Share price has gone up to RM2.30 as at Friday. EPS 5.35 sen x 4 = 21.4 sen. It is traded at PE of 11 times.
24/10/2020 8:51 PM
dompeileedompeilee Bought some Texchem @ 52c 09/09/2020 4:18 PM
SOLD 70% of my Texchem @ 74c
26/10/2020 9:05 AM
Fundamentalist91Guys, don't you see the red flag here? pass few months the founder himself and the company have been selling their own stocks, its not the time to buy again, wait under 0.5c to consider. There's no big moves from texchem, its all the same sushi and chemicals, and so it'll produce the same p/l as it always have.
05/11/2020 1:07 PM
NPRA1985Sinopharm Vaccine (linked to Kanger) is on track for full approval in November or December
“The most promising of these, developed by Wuhan-based Sinopharm, is already being given to frontline workers in the United Arab Emirates. According to Wu Guizhen, chief biosafety expert at the Chinese Center for Disease Control and Prevention, Sinopharm’s candidate is on track for full approval this month or next.”
thestewardNta rm1.885 !! Last q eps over 6 sen ! Don’t miss this boat Both recovery theme n health care theme
08/12/2020 11:09 PM
AlbukharyYup, Texchem is one of the MOST UNDERVALUE STOCK in Bursa Malaysia.
Target Price is RM1.30 minimum.
09/12/2020 1:43 AM
GeneTakavicVaccination started in UK. Anticipated the demand for Face-Shield will be diminishing in next six months, entailing the share price starts to drops, whereas the restaurant business that made RM20 mil loss one time this year would improve. Texchem's dilemma
-0.01 (1.63%) 
